comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 18:00:46 - browse：85692

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： ARCH Venture Partners tops STAT's 2023 biotech VC rankings

knowledge

leisure time

WSS

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Asbestos, a deadly carcinogen, banned by EPA

Methadone treatment changes are coming. Do they go far enough?

Doctors find melanoma drugs effective against rare brain cancer

Physicians and social media: If you see something, say something?

As digital health tech proliferates, a new institute aims to cut through hype

focus

comprehensive

Wikipedia

What does generative AI mean for health care? We asked experts

AI can’t replace a physician’s gut feeling

Medicare proposal to cover medical devices draws a mixed reaction

Orchard's therapy for neuron disease in children wins FDA approval

Duchenne breakthrough therapy leaves behind pioneering families

CVS Caremark has created a new ploy: the drug ‘rebate credit’

In age of alternative facts, a scholarly course on calling out crap

Plastic surgeons increase patient psychiatric screenings

Affirmative action in medical school literally saved lives

SCOTUS questions limit to govt efforts to fight misinformation

focus

5 to watch: Tech startups trying to solve health care's staffing crisis

Future doctors should be trained to promote social change

Baby aspirin cuts fat buildup in liver disease patients, in small study

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Plastic surgeons increase patient psychiatric screenings

Physicians and social media: If you see something, say something?

knowledge

leisure time

focus

focus